Unlike caloric restriction, which triggers adaptive metabolic reprogramming, including enhanced autophagy and neuronal plasticity 69,70 , semaglutide primarily reduces food intake through appetite suppression 71
This pressure does two things
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
The blog specifies that the ideal particle size is between 100200 nm
doi: 10.1017/wsc.2016.34 133 KraujalisP.VenskutonisP
The dosage for adults is generally the same for both diabetes control and weight loss purposes